---
document_datetime: 2025-12-29 09:09:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/talzenna.html
document_name: talzenna.html
version: success
processing_time: 0.1106352
conversion_datetime: 2025-12-30 20:48:30.054544
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Talzenna

[RSS](/en/individual-human-medicine.xml/67216)

##### Authorised

This medicine is authorised for use in the European Union

talazoparib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Talzenna](#news-on)
- [More information on Talzenna](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Talzenna is a cancer medicine used on its own to treat a type of breast cancer (HER2-negative with BRCA mutations) that has spread beyond the original site (locally advanced or metastatic), in patients who have been treated with certain medicines which have stopped working or when these medicines are not suitable.

Talzenna is also used together with another cancer medicine, enzalutamide, to treat adults who have castration-resistant prostate cancer that has spread to other parts of the body (metastatic) and who cannot have chemotherapy. Castration-resistant means that the disease has worsened despite treatment to lower testosterone levels, including surgical removal of the testes.

Talzenna contains the active substance talazoparib

Expand section

Collapse section

## How is Talzenna used?

Talzenna can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.

Talzenna is available as capsules to be taken by mouth once a day. The dose depends on the condition being treated. Treatment should continue for as long as the patient benefits from it and side effects are tolerable. The dose may be reduced or treatment interrupted if certain side effects develop.

For more information about using Talzenna, see the package leaflet or contact your doctor or pharmacist.

## How does Talzenna work?

The active substance in Talzenna, talazoparib, blocks the action of an enzyme called human poly-ADP ribose polymerase (PARP), which is a protein that helps to repair damaged DNA in cells (both normal and cancer cells) during cell division. When the PARP protein is blocked, the damaged DNA in cancer cells cannot be repaired, and as a result the cancer cells die.

## What benefits of Talzenna have been shown in studies?

Talzenna was shown to be effective at increasing the time patients live without their disease getting worse in two main studies.

The first main study involved 431 patients with HER2-negative breast cancer with BRCA mutations whose cancer had spread. Patients treated with Talzenna lived on average for 8.6 months without their disease getting worse compared with 5.6 months for patients treated with the doctor's choice of another cancer medicine.

A second main study involved 805 adults with castration-resistant prostate cancer that had spread to other parts of the body and who had not had chemotherapy. In this study, worsening of the disease could be seen on scans after around 22 months for people who received placebo (a dummy treatment). For those who received Talzenna, this time could not be calculated as not enough people had experienced worsening of their disease after about 28 months of follow up. In both groups, people also received enzalutamide.

## What are the risks associated with Talzenna?

For the full list of side effects and restrictions with Talzenna, see the package leaflet.

The most common side effects with Talzenna (which may affect more than 1 in 5 people) are anaemia (low red blood cell counts), tiredness, nausea (feeling sick), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), thrombocytopenia (low blood levels of platelets), and decreased appetite.

Women must not breastfeed during treatment with Talzenna and for a month after stopping treatment.

## Why is Talzenna authorised in the EU?

Generally the outcome is poor for patients with HER2-negative breast cancer with BRCA mutations whose cancer has spread. Talzenna can increase the time these patients live without their disease getting worse. The medicine has also been found to be effective in the treatment of people with castration-resistant prostate cancer that has spread to other parts of the body and who cannot have chemotherapy. In these people, Talzenna can increase the time they live without their disease getting worse. The side effects with Talzenna were generally acceptable and when needed, manageable with dose modifications or standard supportive medical therapy.

The European Medicines Agency therefore decided that Talzenna's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Talzenna?

The company that holds the marketing authorisation for Talzenna will provide the final results of the study looking at the effectiveness of the medicine together with enzalutamide in the treatment of adults with castration-resistant prostate cancer that has spread to other parts of the body and who cannot have chemotherapy.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Talzenna have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Talzenna are continuously monitored. Side effects reported with Talzenna are carefully evaluated and any necessary action taken to protect patients.

## Other information about Talzenna

Talzenna received a marketing authorisation valid throughout the EU on 20 June 2019.

Talzenna : EPAR - Medicine overview

Reference Number: EMA/242902/2019

English (EN) (118.62 KB - PDF)

**First published:** 08/07/2019

**Last updated:** 16/01/2024

[View](/en/documents/overview/talzenna-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-462)

български (BG) (142.98 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/bg/documents/overview/talzenna-epar-medicine-overview_bg.pdf)

español (ES) (118.33 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/es/documents/overview/talzenna-epar-medicine-overview_es.pdf)

čeština (CS) (140.42 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/cs/documents/overview/talzenna-epar-medicine-overview_cs.pdf)

dansk (DA) (117.5 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/da/documents/overview/talzenna-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.12 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/de/documents/overview/talzenna-epar-medicine-overview_de.pdf)

eesti keel (ET) (116.34 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/et/documents/overview/talzenna-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.55 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/el/documents/overview/talzenna-epar-medicine-overview_el.pdf)

français (FR) (119.21 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/fr/documents/overview/talzenna-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.56 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/hr/documents/overview/talzenna-epar-medicine-overview_hr.pdf)

italiano (IT) (116.93 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/it/documents/overview/talzenna-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.92 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/lv/documents/overview/talzenna-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.28 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/lt/documents/overview/talzenna-epar-medicine-overview_lt.pdf)

magyar (HU) (140.86 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/hu/documents/overview/talzenna-epar-medicine-overview_hu.pdf)

Malti (MT) (142.45 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/mt/documents/overview/talzenna-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.66 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/nl/documents/overview/talzenna-epar-medicine-overview_nl.pdf)

polski (PL) (142.28 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/pl/documents/overview/talzenna-epar-medicine-overview_pl.pdf)

português (PT) (118.83 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/pt/documents/overview/talzenna-epar-medicine-overview_pt.pdf)

română (RO) (137.82 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/ro/documents/overview/talzenna-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.87 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/sk/documents/overview/talzenna-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.62 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/sl/documents/overview/talzenna-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.04 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/fi/documents/overview/talzenna-epar-medicine-overview_fi.pdf)

svenska (SV) (116.73 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

16/01/2024

[View](/sv/documents/overview/talzenna-epar-medicine-overview_sv.pdf)

Talzenna : EPAR - Risk management plan

English (EN) (1.18 MB - PDF)

**First published:** 08/07/2019

**Last updated:** 11/09/2024

[View](/en/documents/rmp/talzenna-epar-risk-management-plan_en.pdf)

## Product information

Talzenna : EPAR - Product Information

English (EN) (1.2 MB - PDF)

**First published:** 08/07/2019

**Last updated:** 18/07/2025

[View](/en/documents/product-information/talzenna-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-618)

български (BG) (1.34 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/bg/documents/product-information/talzenna-epar-product-information_bg.pdf)

español (ES) (1.72 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/es/documents/product-information/talzenna-epar-product-information_es.pdf)

čeština (CS) (1.49 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/cs/documents/product-information/talzenna-epar-product-information_cs.pdf)

dansk (DA) (1.25 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/da/documents/product-information/talzenna-epar-product-information_da.pdf)

Deutsch (DE) (1.51 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/de/documents/product-information/talzenna-epar-product-information_de.pdf)

eesti keel (ET) (1009.05 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/et/documents/product-information/talzenna-epar-product-information_et.pdf)

ελληνικά (EL) (1.51 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/el/documents/product-information/talzenna-epar-product-information_el.pdf)

français (FR) (1.19 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/fr/documents/product-information/talzenna-epar-product-information_fr.pdf)

hrvatski (HR) (1.17 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/hr/documents/product-information/talzenna-epar-product-information_hr.pdf)

íslenska (IS) (791.17 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/is/documents/product-information/talzenna-epar-product-information_is.pdf)

italiano (IT) (1.71 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/it/documents/product-information/talzenna-epar-product-information_it.pdf)

latviešu valoda (LV) (807.3 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/lv/documents/product-information/talzenna-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.17 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/lt/documents/product-information/talzenna-epar-product-information_lt.pdf)

magyar (HU) (1.19 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/hu/documents/product-information/talzenna-epar-product-information_hu.pdf)

Malti (MT) (870.37 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/mt/documents/product-information/talzenna-epar-product-information_mt.pdf)

Nederlands (NL) (816.01 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/nl/documents/product-information/talzenna-epar-product-information_nl.pdf)

norsk (NO) (1012.32 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/no/documents/product-information/talzenna-epar-product-information_no.pdf)

polski (PL) (1.34 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/pl/documents/product-information/talzenna-epar-product-information_pl.pdf)

português (PT) (917.13 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/pt/documents/product-information/talzenna-epar-product-information_pt.pdf)

română (RO) (1.3 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/ro/documents/product-information/talzenna-epar-product-information_ro.pdf)

slovenčina (SK) (1.3 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/sk/documents/product-information/talzenna-epar-product-information_sk.pdf)

slovenščina (SL) (1.38 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/sl/documents/product-information/talzenna-epar-product-information_sl.pdf)

Suomi (FI) (1.43 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/fi/documents/product-information/talzenna-epar-product-information_fi.pdf)

svenska (SV) (1.16 MB - PDF)

**First published:**

08/07/2019

**Last updated:**

18/07/2025

[View](/sv/documents/product-information/talzenna-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** X/0022 19/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Talzenna : EPAR - All Authorised presentations

English (EN) (27.92 KB - PDF)

**First published:** 08/07/2019

**Last updated:** 29/08/2025

[View](/en/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-975)

български (BG) (29.63 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/bg/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.38 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/es/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.83 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/cs/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27.7 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/da/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.96 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/de/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (28.7 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/et/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (30.17 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/el/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_el.pdf)

français (FR) (27.17 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/fr/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.81 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/hr/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.7 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/is/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.74 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/it/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (27.79 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/lv/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (28.4 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/lt/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.06 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/hu/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (29.27 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/mt/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.35 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/nl/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.78 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/no/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.16 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/pl/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.94 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/pt/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_pt.pdf)

română (RO) (27.26 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/ro/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.04 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/sk/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.08 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/sl/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (26.79 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/fi/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.11 KB - PDF)

**First published:**

08/07/2019

**Last updated:**

29/08/2025

[View](/sv/documents/all-authorised-presentations/talzenna-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Talzenna Active substance talazoparib International non-proprietary name (INN) or common name talazoparib Therapeutic area (MeSH) Breast Neoplasms Anatomical therapeutic chemical (ATC) code L01XK04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Treatment with Talzenna should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.

**Patient selection**

Breast cancer: Patients should be selected for the treatment of breast cancer with Talzenna based on the presence of deleterious or suspected deleterious germline BRCA mutations determined by an experienced laboratory using a validated test method.

Genetic counselling for patients with BRCA mutations should be performed according to local regulations, as applicable.

Prostate cancer: There is no requirement for tumour mutation testing for selection of patients with mCRPC for treatment with Talzenna.

## Authorisation details

EMA product number EMEA/H/C/004674 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 26/04/2019 Marketing authorisation issued 20/06/2019 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Talzenna : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.05 KB - PDF)

**First published:** 18/07/2025

[View](/en/documents/procedural-steps-after/talzenna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Talzenna : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (188.72 KB - PDF)

**First published:** 17/06/2020

**Last updated:** 29/08/2025

[View](/en/documents/procedural-steps-after/talzenna-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Talzenna-H-C-4674-X-0015-G : EPAR - Assessment report - Variation

Reference Number: EMA/570477/2023

English (EN) (4.39 MB - PDF)

**First published:** 16/01/2024

[View](/en/documents/variation-report/talzenna-h-c-4674-x-0015-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Talzenna (X-15-G)

Adopted

Reference Number: EMA/CHMP/488483/2023

English (EN) (132.2 KB - PDF)

**First published:** 10/11/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-talzenna-x-15-g_en.pdf)

## Initial marketing authorisation documents

Talzenna : EPAR - Public assessment report

Reference Number: EMA/270498/2019

English (EN) (4.38 MB - PDF)

**First published:** 08/07/2019

[View](/en/documents/assessment-report/talzenna-epar-public-assessment-report_en.pdf)

#### News on Talzenna

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023) 10/11/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019) 26/04/2019

#### More information on Talzenna

- [EMEA-002066-PIP02-20 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002066-pip02-20)
- [EMEA-002066-PIP01-20 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002066-pip01-20)
- [Therapy of metastatic castration-resistant prostate cancer with Talazoparib + Enzalutamide under real world conditions in Germany - an observational medical chart review study (PROTEGE study) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000593)
- [Machine learning prediction of anemia events before and after talazoparib dose modification using TALAPRO-2 phase 3 trial data - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000344)
- [An International, Multicenter, Prospective Non-Interventional Study of Real-World Treatment Outcomes in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) treated with Talazoparib and Enzalutamide (TALENZA) - post-authorisation study](https://catalogues.ema.europa.eu/study/106720)
- [A national, multi-centre, longitudinal observational study evaluating the efficacy and safety under real-life conditions of use of TALZENNA® (talazoparib) in patients with somatic or germline BRCA mutated HER2 negative, locally advanced or metastatic breast cancer (Vital Study) - post-authorisation study](https://catalogues.ema.europa.eu/study/33781)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/08/2025

## Share this page

[Back to top](#main-content)